Агонисты дофаминовых рецепторов и проблема эквивалентности доз

1. Thobois S, Delamarre-Damier F, Derkinderen P. Treatment of motor dysfunction in Parkinson’s disease: An overview. Clin Neurol Neurosurg 2005; 107: 269–81.
2. Rinne UK. Early combination of bromocriptine and levodopa in the treatment of Parkinson’s disease: A 5-year follow-up. Neurology 1987; 37: 826–8.
3. Montastruc JL, Rascol O, Senard JM, Rascol A. A randomised controlled study comparing bromocriptine to whtich levodops was leter added, with Parkinson’s disease: A 5-year follow-up. J Neurol Neurosurg Psychiatry 1994; 57: 1034–38.
4. Adler CH, Sethi KD, Hauser RA et al., for the Ropinirole Study Group. Ropinirole for the treatment of early Parkinson’s disease [published correction appears in Neurology. 1997; 49: 1484]. Neurology 1997; 49: 393–9.
5. Hely MA, Morris JG, Traficante R et al. The Sydney Multicentre Study of Parkinson’s disease: Progression and mortality at 10 years. J Neurol Neurosurg Psychiatry 1999; 67: 300–7.
6. Clarke CE, Deane KH. Ropinirole versus bromocriptine for levodopa-induced complications in Parkinson’s disease. Cochrane Database Syst Rev 2001; 1: CD001517.
7. Clarke CE, Speller JM. Pergolide versus bromocriptine for levodopa-induced motoer complications in Parkinson’s disease. Cochrane Database Syst Rev 2000; 2: CD000236.
8. Rinne UK, Bracco F, Chouza C et al., for the PKDS009 Study Group. Early treatment of Parkinson’s disease with cabergoline de;ays the onset of motor complications. Result of a double-bling levodopa controlled trial. Drugs 1998; 55 (Suppl. 1): 23–30.
9. Barone P, Bravi D, Bermejo-Pareja F et al., for the Pergolide Monotherapy Study Group. Pergolide monotherapy in the treatment of early PD. A ramdomized, controlled study. Neurology 1999; 53: 573–9.
10. Rascol O, Brooks DJ, Dorczyn AD et al., for the 056 Study Group. A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. N Engl J Med 2000; 342: 1484–91.
11. Leberman AN, Neophytides A, Leibowitz M et al. Comparative efficacy of pergolide and bromocriptine in patients with advanced Parkinson’s disease. Adv Neurol 1983; 37: 95–108.
12. Lieberman A, Olanow CW, Sethi K et al., for the Ropinirole Study Group. A multicenter trial of ropinirole as adjunct treatment for Parkinson’s disease [published correction appears in Neurology. 1999; 52: 435]. Neurology 1998; 51: 1057–62.
13. Pezzoli G, Martignoni E, pacchetti C et al. A crossover, controlled study comparing pergolide with bromocriptine as an adjunct to levodopa for the treatment of Parkinson’s disease. Neurology 1995; 45 (Suppl. 3): S22–7.
14. Inzelberg R, Nisipeanu P, Rabey JM et al. Double-blind comparison of cabergoline and bromocriptine in Parkinson’s disease patients with motor fluctuations. Neurology 1996; 47: 785–8.
15. Guttman M, for the International Pramipexole-Bromocriptine Study Group. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson’s disease. Neurology 1997; 49: 1060–5.
16. Brunt ER, Brooks DJ, Korczyn AD et al. A six-month multicentre, double-blind, bromocriptine-controlled study of the safety and efficacy of ropinirole in the treatment of patients with Pardinson’s disease not optimally controlled by L-dopa. J Neural Transm 2002; 109: 489–502.
17. Ziegler M, Castro-Caldas A, Del Signore S, Rascol O. Efficacy of piribedil as early combination to levodopa in patients with stable Parkinson’s disease: A 6-month, randomized, placebo-controlled study. Mov Disord 2003; 18: 418–25.
18. Rascol O, Pathak A, Bagheri H, Montastruc JL. New concerns about old drugs: Valvular heart disease on ergot dervative dopamine agonists as an exemplary situation of pharmacovigilance. Mov Disord 2004; 19: 611–3.
19. Fsctor SA, Sanchez-Ramos JR, Weiner WJ. Parkinson’s disease: An open label trial of pergolide in patients failing bromocriptine therapy. J Neurol Neurosurg Psychiatry 1988; 51: 529–33.
20. Goetz CG, Blasucci L, Stebbins GT. Switching dopamine agonists in advanced Parkinson’s disease: il rapid titration preferable to slow? Neurology 1997; 52: 1227–9.
21. Canesi M, Antonini A, Mariani CB et al. An overnight switch to roinirole therapy in patients with Parkinson’s disease. J Neural Transm 199; 106: 925–9.
22. Thobois S. Proposed dose equivalence for rapid switch between dopamine receptor agonists in Parkinson’s disease: a review of the literature. Clinical Therapeutics 2006; 28: 1–12.
23. Castro-Caldas A, Delwaide P, Jost W et al. The Parkinson-CONTROL study: A 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson’s disease. Mov Disord. In press.
24. Aguilar M, Delwaide P, Linazasoro G et al. A double-blind 2-year extension of the Parkinson-CONTROL Study comparing fixed doses of piribedil (150 mg/day) an bromocriptine (25 mg/day) in early combination with L-dopa in Parkinson’s disease. Mov Disord. 2005; 20 (Suppl. 10): 259. Abstract.
25. Pezzoli G, Martignoni E, Pacchetti C et al. Pergolide compared with bromocriptine on Parkinson’s disease: A multicenter, crossover, controlled study. Mov Disord 1994; 9: 431–6.
26. Korczyn AD, Brooks DJ, Brunt ER et al., for the 053 Study Group. Ropinirole versus bromocriptine in the treatment of early Parkinson’s disease: A 6-month interim report of a 3-year study. Mov Disord 1998; 13: 46–51.
27. Korczyn AD, Brunt ER, Larsen JP et al., for the 053 Study Group. A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson’s disease [publiched correction appear in Neurology. 1999; 53: 1162]. Neurology 1999; 53: 364–70.
28. Gimenez-Roldan S, Esteban EM, Mateo D. Switching form bromocriptine to ropinirole in patients with advanced Parkinson’s disease: Open-label pilot responses to three different doseratios. Clin Neuropharmacol 2001; 24: 346–51.
29. Olanow CW, Agid Y, Mizuno Y et al. Levodopa in the treatment of Parkinson’s disease: Current controversies [published correction appears in Mov Disord. 2005; 20: 645]. Mov Disord 2004; 19: 997–1005.